The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
ALL represents 20% of all cancers diagnosed in patients aged less than 20 years, or more than 3000 new cases annually. Three percent of children who have ALL have Ph+ disease.
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Bristol-Myers Squibb. Published January 2, 2019. https://bit.ly/2F230c5?rel=0" . Accessed January 2, 2019.
... to read the full story